Sampre Nutritions Ltd (BSE: 530617) announced that its Board of Directors, in the meeting held on October 3, 2025, approved foreign currency convertible bonds (FCCBs) totaling USD 4 million (Rs. 355.06 crore). The proceeds will fund expansion in Egypt and Liberia, strengthening the company’s presence in high-growth markets. ARIES Capital Ltd has been appointed as Lead Arranger, with bonds to be listed on Afrinex Exchange, Mauritius, from October 10–15, 2025.
The company earlier approved a stock split of one Rs.10 share into two Rs.5 shares and a 1:1 bonus issue. Bonus shares will be credited by December 19, 2025, utilizing Rs. 21.55 crore from the securities premium account, which had Rs. 59.86 crore as on March 31, 2025.
Sampre also completed the conversion of 5.5 lakh warrants into equity shares. Of these, 5 lakh shares were allotted to promoter group member Mr. Brahma Gurbani and 50,000 shares to Mr. Vishal Ratan Gurbani, following a special resolution passed in December 2023.
The company entered into manufacturing agreements with Tolaram Wellness Ltd., Nigeria, and Rama Exports in August 2025. The contracts, together valued at Rs. 45 crore, will enhance Sampre’s nutraceutical and food product portfolio and contribute to consistent revenue growth.
For Q1FY26, Sampre reported Rs. 10.87 crore revenue — a 141% YoY increase — and a net profit of Rs. 70.76 lakh, up 615% YoY. The company also received recognition in the India 5000 Best MSME Awards 2024 for excellence in quality and customer satisfaction.
--
.JPG)
0 Comments